ArticleClinical ophthalmology (Auckland, N.Z.)2025
Ahmed Glaucoma Valve in Aniridia.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate long-term clinical outcomes after Ahmed Glaucoma Valve implantation in glaucoma associated with aniridia. Methods: This was a retrospective, noncomparative, consecutive, interventional case series of 20 eyes in 15 patients with aniridic glaucoma treated with the Ahmed Glaucoma Valve (Model FP7, New World Medical, Rancho Cucamonga, CA). Patient records were reviewed for intraocular pressure (IOP), number of glaucoma medications, surgical success (5 mmHg ≤ IOP ≤ 21 mmHg and ≥20% from baseline, without additional glaucoma surgery, and without loss of light perception vision), and complications. Results: The IOP and number of glaucoma medications were significantly reduced at all time points after surgery. The mean IOP was 31.6 ± 8.4 and 15.6 ± 3.0 mmHg at baseline and 7 years after surgery, respectively (P<0.0005). At baseline and 7 years after surgery, the average number of medications was 3.0 ± 0.7 and 0.8 ± 0.8, respectively (P<0.0005). The cumulative probability of success was 95% at 7 years after surgery. Transient postoperative complications included shallow anterior chamber in 1 eye (5%) and choroidal effusion in 2 eyes (10%). Complications in the late postoperative period included tube repositioning in 4 eyes (20%), patch graft for tube exposure in 3 eyes (15%), and cataract in 1 eye (5%). Complications were resolved without vision loss in all patients. Conclusion: Ahmed Glaucoma Valve implantation is effective for long-term control of IOP in patients with aniridic glaucoma. Complications were not associated with vision loss.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.